Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Intrinsic tumor necrosis factor-α pathway is activated in a subset of patients with focal segmental glomerulosclerosis.

Chung CF, Kitzler T, Kachurina N, Pessina K, Babayeva S, Bitzan M, Kaskel F, Colmegna I, Alachkar N, Goodyer P, Cybulsky AV, Torban E.

PLoS One. 2019 May 16;14(5):e0216426. doi: 10.1371/journal.pone.0216426. eCollection 2019.

2.

Preservation of circadian rhythms by the protein folding chaperone, BiP.

Pickard A, Chang J, Alachkar N, Calverley B, Garva R, Arvan P, Meng QJ, Kadler KE.

FASEB J. 2019 Jun;33(6):7479-7489. doi: 10.1096/fj.201802366RR. Epub 2019 Mar 19.

3.

Renal Complications in Pregnancy Preceding Glomerulonephropathy Diagnosis.

Oliverio AL, Zee J, Mariani LH, Reynolds ML, O'Shaughnessy M, Hendren EM, Alachkar N, Herreshoff E, Rizk DV, Nester CM, Steinke J, Twombley KE, Hladunewich MA.

Kidney Int Rep. 2018 Oct 25;4(1):159-162. doi: 10.1016/j.ekir.2018.10.012. eCollection 2019 Jan. No abstract available.

4.

Monitoring suPAR levels in post-kidney transplant focal segmental glomerulosclerosis treated with therapeutic plasma exchange and rituximab.

Alachkar N, Li J, Matar D, Vujjini V, Alasfar S, Tracy M, Reiser J, Wei C.

BMC Nephrol. 2018 Dec 17;19(1):361. doi: 10.1186/s12882-018-1177-x.

5.

ACTH Gel in Resistant Focal Segmental Glomerulosclerosis After Kidney Transplantation.

Alhamad T, Manllo Dieck J, Younus U, Matar D, Alasfar S, Vujjini V, Wall D, Kanawati B, Reiser J, Brennan DC, Alachkar N.

Transplantation. 2019 Jan;103(1):202-209. doi: 10.1097/TP.0000000000002320.

PMID:
29894413
6.

The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials.

Haas M, Loupy A, Lefaucheur C, Roufosse C, Glotz D, Seron D, Nankivell BJ, Halloran PF, Colvin RB, Akalin E, Alachkar N, Bagnasco S, Bouatou Y, Becker JU, Cornell LD, van Huyen JPD, Gibson IW, Kraus ES, Mannon RB, Naesens M, Nickeleit V, Nickerson P, Segev DL, Singh HK, Stegall M, Randhawa P, Racusen L, Solez K, Mengel M.

Am J Transplant. 2018 Feb;18(2):293-307. doi: 10.1111/ajt.14625. Epub 2018 Jan 21.

7.

Rituximab and Therapeutic Plasma Exchange in Recurrent Focal Segmental Glomerulosclerosis Postkidney Transplantation.

Alasfar S, Matar D, Montgomery RA, Desai N, Lonze B, Vujjini V, Estrella MM, Manllo Dieck J, Khneizer G, Sever S, Reiser J, Alachkar N.

Transplantation. 2018 Mar;102(3):e115-e120. doi: 10.1097/TP.0000000000002008.

8.

Nontraditional sites for vascular anastomoses to enable kidney transplantation in patients with major systemic venous thromboses.

Lonze BE, Dagher NN, Alachkar N, Jackson AM, Montgomery RA.

Clin Transplant. 2017 Dec;31(12). doi: 10.1111/ctr.13127. Epub 2017 Nov 28.

PMID:
28960455
9.

Outcomes and risk stratification for late antibody-mediated rejection in recipients of ABO-incompatible kidney transplants: a retrospective study.

Lonze BE, Bae S, Kraus ES, Holechek MJ, King KE, Alachkar N, Naqvi FF, Dagher NN, Sharif A, Desai NM, Segev DL, Montgomery RA.

Transpl Int. 2017 Sep;30(9):874-883. doi: 10.1111/tri.12969. Epub 2017 Jun 2.

10.

Quantitative characterization of T-cell repertoire and biomarkers in kidney transplant rejection.

Alachkar H, Mutonga M, Kato T, Kalluri S, Kakuta Y, Uemura M, Imamura R, Nonomura N, Vujjini V, Alasfar S, Rabb H, Nakamura Y, Alachkar N.

BMC Nephrol. 2016 Nov 21;17(1):181.

11.

The Banff 2015 Kidney Meeting Report: Current Challenges in Rejection Classification and Prospects for Adopting Molecular Pathology.

Loupy A, Haas M, Solez K, Racusen L, Glotz D, Seron D, Nankivell BJ, Colvin RB, Afrouzian M, Akalin E, Alachkar N, Bagnasco S, Becker JU, Cornell L, Drachenberg C, Dragun D, de Kort H, Gibson IW, Kraus ES, Lefaucheur C, Legendre C, Liapis H, Muthukumar T, Nickeleit V, Orandi B, Park W, Rabant M, Randhawa P, Reed EF, Roufosse C, Seshan SV, Sis B, Singh HK, Schinstock C, Tambur A, Zeevi A, Mengel M.

Am J Transplant. 2017 Jan;17(1):28-41. doi: 10.1111/ajt.14107.

12.

Recurrent IgA Nephropathy After Kidney Transplantation.

Nijim S, Vujjini V, Alasfar S, Luo X, Orandi B, Delp C, Desai NM, Montgomery RA, Lonze BE, Alachkar N.

Transplant Proc. 2016 Oct;48(8):2689-2694. doi: 10.1016/j.transproceed.2016.08.011.

PMID:
27788802
13.

Successful Renal Transplantation of Deceased Donor Kidneys With 100% Glomerular Fibrin Thrombi and Acute Renal Failure Due to Disseminated Intravascular Coagulation.

Soares KC, Arend LJ, Lonze BE, Desai NM, Alachkar N, Naqvi F, Montgomery RA.

Transplantation. 2017 Jun;101(6):1134-1138. doi: 10.1097/TP.0000000000001386.

PMID:
27490412
14.

Ammonia Level and Mortality in Acute Liver Failure: A Single-Center Experience.

Niranjan-Azadi AM, Araz F, Patel YA, Alachkar N, Alqahtani S, Cameron AM, Stevens RD, Gurakar A.

Ann Transplant. 2016 Aug 2;21:479-83.

15.

Splenic Irradiation for the Treatment of Severe Antibody-Mediated Rejection.

Orandi BJ, Lonze BE, Jackson A, Terezakis S, Kraus ES, Alachkar N, Bagnasco SM, Segev DL, Orens JB, Montgomery RA.

Am J Transplant. 2016 Oct;16(10):3041-3045. doi: 10.1111/ajt.13882. Epub 2016 Jun 27.

16.

Membranoproliferative glomerulonephritis recurrence after kidney transplantation: using the new classification.

Alasfar S, Carter-Monroe N, Rosenberg AZ, Montgomery RA, Alachkar N.

BMC Nephrol. 2016 Jan 11;17:7. doi: 10.1186/s12882-015-0219-x.

17.

Novel unbiased assay for circulating podocyte-toxic factors associated with recurrent focal segmental glomerulosclerosis.

Kachurina N, Chung CF, Benderoff E, Babayeva S, Bitzan M, Goodyer P, Kitzler T, Matar D, Cybulsky AV, Alachkar N, Torban E.

Am J Physiol Renal Physiol. 2016 May 15;310(10):F1148-56. doi: 10.1152/ajprenal.00349.2015. Epub 2015 Dec 30.

18.

Presentation and Outcomes of C4d-Negative Antibody-Mediated Rejection After Kidney Transplantation.

Orandi BJ, Alachkar N, Kraus ES, Naqvi F, Lonze BE, Lees L, Van Arendonk KJ, Wickliffe C, Bagnasco SM, Zachary AA, Segev DL, Montgomery RA.

Am J Transplant. 2016 Jan;16(1):213-20. doi: 10.1111/ajt.13434. Epub 2015 Aug 28.

19.

Quantifying renal allograft loss following early antibody-mediated rejection.

Orandi BJ, Chow EH, Hsu A, Gupta N, Van Arendonk KJ, Garonzik-Wang JM, Montgomery JR, Wickliffe C, Lonze BE, Bagnasco SM, Alachkar N, Kraus ES, Jackson AM, Montgomery RA, Segev DL.

Am J Transplant. 2015 Feb;15(2):489-98. doi: 10.1111/ajt.12982. Epub 2015 Jan 21.

20.

Atypical hemolytic uremic syndrome post-kidney transplantation: two case reports and review of the literature.

Alasfar S, Alachkar N.

Front Med (Lausanne). 2014 Dec 12;1:52. doi: 10.3389/fmed.2014.00052. eCollection 2014. Review.

21.

Frailty, mycophenolate reduction, and graft loss in kidney transplant recipients.

McAdams-DeMarco MA, Law A, Tan J, Delp C, King EA, Orandi B, Salter M, Alachkar N, Desai N, Grams M, Walston J, Segev DL.

Transplantation. 2015 Apr;99(4):805-10. doi: 10.1097/TP.0000000000000444.

22.

Management of hepatitis C infection among patients with renal failure.

Latt NL, Araz F, Alachkar N, Durand CM, Gurakar A.

Minerva Gastroenterol Dietol. 2015 Mar;61(1):39-49. Epub 2014 Nov 12. Review.

PMID:
25390288
23.

Frailty and mortality in kidney transplant recipients.

McAdams-DeMarco MA, Law A, King E, Orandi B, Salter M, Gupta N, Chow E, Alachkar N, Desai N, Varadhan R, Walston J, Segev DL.

Am J Transplant. 2015 Jan;15(1):149-54. doi: 10.1111/ajt.12992. Epub 2014 Oct 30.

24.

Sarcoidosis in native and transplanted kidneys: incidence, pathologic findings, and clinical course.

Bagnasco SM, Gottipati S, Kraus E, Alachkar N, Montgomery RA, Racusen LC, Arend LJ.

PLoS One. 2014 Oct 20;9(10):e110778. doi: 10.1371/journal.pone.0110778. eCollection 2014.

25.

A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation.

Delville M, Sigdel TK, Wei C, Li J, Hsieh SC, Fornoni A, Burke GW, Bruneval P, Naesens M, Jackson A, Alachkar N, Canaud G, Legendre C, Anglicheau D, Reiser J, Sarwal MM.

Sci Transl Med. 2014 Oct 1;6(256):256ra136. doi: 10.1126/scitranslmed.3008538.

26.

Case series: CTLA4-IgG1 therapy in minimal change disease and focal segmental glomerulosclerosis.

Garin EH, Reiser J, Cara-Fuentes G, Wei C, Matar D, Wang H, Alachkar N, Johnson RJ.

Pediatr Nephrol. 2015 Mar;30(3):469-77. doi: 10.1007/s00467-014-2957-6. Epub 2014 Sep 20.

27.

Diabetes mellitus in the transplanted kidney.

Peev V, Reiser J, Alachkar N.

Front Endocrinol (Lausanne). 2014 Aug 27;5:141. doi: 10.3389/fendo.2014.00141. eCollection 2014. Review.

28.

Permeability factors in focal and segmental glomerulosclerosis.

Reiser J, Nast CC, Alachkar N.

Adv Chronic Kidney Dis. 2014 Sep;21(5):417-21. doi: 10.1053/j.ackd.2014.05.010. Review.

29.

Eculizumab and splenectomy as salvage therapy for severe antibody-mediated rejection after HLA-incompatible kidney transplantation.

Orandi BJ, Zachary AA, Dagher NN, Bagnasco SM, Garonzik-Wang JM, Van Arendonk KJ, Gupta N, Lonze BE, Alachkar N, Kraus ES, Desai NM, Locke JE, Racusen LC, Segev DL, Montgomery RA.

Transplantation. 2014 Oct 27;98(8):857-63. doi: 10.1097/TP.0000000000000298.

PMID:
25121475
30.

Blood dendritic cell levels associated with impaired IL-12 production and T-cell deficiency in patients with kidney disease: implications for post-transplant viral infections.

Chen P, Sun Q, Huang Y, Atta MG, Turban S, Segev DL, Marr KA, Naqvi FF, Alachkar N, Kraus ES, Womer KL.

Transpl Int. 2014 Oct;27(10):1069-76. doi: 10.1111/tri.12381. Epub 2014 Aug 20.

31.

Late antibody-mediated rejection in renal allografts: outcome after conventional and novel therapies.

Gupta G, Abu Jawdeh BG, Racusen LC, Bhasin B, Arend LJ, Trollinger B, Kraus E, Rabb H, Zachary AA, Montgomery RA, Alachkar N.

Transplantation. 2014 Jun 27;97(12):1240-6. doi: 10.1097/01.TP.0000442503.85766.91.

PMID:
24937198
32.

Atypical hemolytic uremic syndrome recurrence after kidney transplantation.

Matar D, Naqvi F, Racusen LC, Carter-Monroe N, Montgomery RA, Alachkar N.

Transplantation. 2014 Dec 15;98(11):1205-12. doi: 10.1097/TP.0000000000000200.

PMID:
24933457
33.

Abatacept in B7-1-positive proteinuric kidney disease.

Alachkar N, Carter-Monroe N, Reiser J.

N Engl J Med. 2014 Mar 27;370(13):1263-4. doi: 10.1056/NEJMc1400502. No abstract available.

PMID:
24670180
34.

Diagnosing hepatitis C virus and improved outcomes in overall and kidney graft survival among simultaneous liver-kidney transplant recipients in the post-MELD era.

Latt NL, Alachkar N, Taydas E, Cameron A, Gurakar A.

Exp Clin Transplant. 2014 Mar;12 Suppl 1:45-9. Erratum in: Exp Clin Transplant. 2014 Apr;12(2):173. Alachka, Nada [corrected to Alachkar, Nada].

35.

Time course of pathologic changes in kidney allografts of positive crossmatch HLA-incompatible transplant recipients.

Bagnasco SM, Zachary AA, Racusen LC, Arend LJ, Carter-Monroe N, Alachkar N, Nazarian SM, Lonze BE, Montgomery RA, Kraus ES.

Transplantation. 2014 Feb 27;97(4):440-5. doi: 10.1097/01.TP.0000437177.40551.f4.

PMID:
24531821
36.

Histologic phenotype on 1-year posttransplantation biopsy and allograft survival in HLA-incompatible kidney transplants.

Sharif A, Kraus ES, Zachary AA, Lonze BE, Nazarian SM, Segev DL, Alachkar N, Arend LJ, Bagnasco SM, Racusen LC, Montgomery RA.

Transplantation. 2014 Mar 15;97(5):541-7. doi: 10.1097/01.TP.0000442513.27641.7e.

PMID:
24521779
37.

Proteinuria: abate or applaud abatacept in proteinuric kidney disease?

Reiser J, Alachkar N.

Nat Rev Nephrol. 2014 Mar;10(3):128-30. doi: 10.1038/nrneph.2013.276. Epub 2013 Dec 24.

PMID:
24375054
38.

Podocyte effacement closely links to suPAR levels at time of posttransplantation focal segmental glomerulosclerosis occurrence and improves with therapy.

Alachkar N, Wei C, Arend LJ, Jackson AM, Racusen LC, Fornoni A, Burke G, Rabb H, Kakkad K, Reiser J, Estrella MM.

Transplantation. 2013 Oct 15;96(7):649-56. doi: 10.1097/TP.0b013e31829eda4f.

39.

Reply to "Defining the benefits of desensitization therapy".

Singer AL, Alachkar N, Montgomery RA, Zachary AA.

Transplantation. 2013 Mar 27;95(6):e33. doi: 10.1097/TP.0b013e3182845ffb. No abstract available.

PMID:
23507652
40.

Angiotensin antibodies and focal segmental glomerulosclerosis.

Alachkar N, Gupta G, Montgomery RA.

N Engl J Med. 2013 Mar 7;368(10):971-3. doi: 10.1056/NEJMc1207233. No abstract available.

PMID:
23465123
41.

Hepatitis C virus and its renal manifestations: a review and update.

Latt N, Alachkar N, Gurakar A.

Gastroenterol Hepatol (N Y). 2012 Jul;8(7):434-45.

42.

Incompatible kidney transplantation: a brief overview of the past, present and future.

Sharif A, Alachkar N, Kraus E.

QJM. 2012 Dec;105(12):1141-50. doi: 10.1093/qjmed/hcs154. Epub 2012 Aug 20. Review.

PMID:
22908321
43.

Infusion of high-dose intravenous immunoglobulin fails to lower the strength of human leukocyte antigen antibodies in highly sensitized patients.

Alachkar N, Lonze BE, Zachary AA, Holechek MJ, Schillinger K, Cameron AM, Desai NM, Dagher NN, Segev DL, Montgomery RA, Singer AL.

Transplantation. 2012 Jul 27;94(2):165-71. doi: 10.1097/TP.0b013e318253f7b6.

PMID:
22735712
44.

Incidence and outcomes of BK virus allograft nephropathy among ABO- and HLA-incompatible kidney transplant recipients.

Sharif A, Alachkar N, Bagnasco S, Geetha D, Gupta G, Womer K, Arend L, Racusen L, Montgomery R, Kraus E.

Clin J Am Soc Nephrol. 2012 Aug;7(8):1320-7. doi: 10.2215/CJN.00770112. Epub 2012 May 24.

45.

Eculizumab for the treatment of two recurrences of atypical hemolytic uremic syndrome in a kidney allograft.

Alachkar N, Bagnasco SM, Montgomery RA.

Transpl Int. 2012 Aug;25(8):e93-5. doi: 10.1111/j.1432-2277.2012.01497.x. Epub 2012 May 17. No abstract available.

46.

Rescue kidney paired donation as emergency salvage for failed desensitization.

Sharif A, Zachary AA, Hiller J, Segev D, Alachkar N, Kraus ES, Desai NM, Dagher NN, Singer AL, Montgomery RA.

Transplantation. 2012 Apr 15;93(7):e27-9. doi: 10.1097/TP.0b013e318249b10e. No abstract available.

PMID:
22450596
47.

Serum and urinary biomarkers in acute kidney transplant rejection.

Alachkar N.

Nephrol Ther. 2012 Feb;8(1):13-9. doi: 10.1016/j.nephro.2011.07.409. Epub 2011 Oct 21. Review.

PMID:
22018843
48.

Urinary biomarkers in acute kidney transplant dysfunction.

Alachkar N, Rabb H, Jaar BG.

Nephron Clin Pract. 2011;118(2):c173-81; discussion c181. doi: 10.1159/000321381. Epub 2010 Dec 16. Review.

49.

Molecular imaging of the kidneys.

Szabo Z, Alachkar N, Xia J, Mathews WB, Rabb H.

Semin Nucl Med. 2011 Jan;41(1):20-8. doi: 10.1053/j.semnuclmed.2010.09.003. Review.

50.

Stem cell factor, interleukin-16, and interleukin-2 receptor alpha are predictive biomarkers for delayed and slow graft function.

Alachkar N, Ugarte R, Huang E, Womer KL, Montgomery R, Kraus E, Rabb H.

Transplant Proc. 2010 Nov;42(9):3399-405. doi: 10.1016/j.transproceed.2010.06.013.

PMID:
21094786

Supplemental Content

Loading ...
Support Center